XML 32 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
ft²
shares
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
ft²
shares
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Number of Operating Segments     1    
Revenue from Contract with Customer, Excluding Assessed Tax $ 397,060 $ 879,597 $ 2,212,271 $ 2,186,577  
Accounts Receivable, Allowance for Credit Loss, Ending Balance 0   0   $ 0
Operating Lease, Expense 15,000   45,000    
Operating Lease, Liability 148,000   148,000    
Operating Lease, Right-of-Use Asset 153,112   153,112   0
Deferred Tax Assets, Net $ 17,100,000   $ 17,100,000   $ 15,500,000
Deferred Tax Assets, Valuation Allowance Coverage, Percent     100.00%   100.00%
Other Income     $ 1,018,000 $ 250,000  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 5,281,097   5,281,097    
Share-Based Payment Arrangement [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 5,658,811   5,658,811    
Restricted Stock Units (RSUs) [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 163,044   163,044    
Share-Based Payment Arrangement, Option [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 5,495,767   5,495,767    
Weighted Average [Member]          
Operating Lease, Right-of-Use Asset $ 153,000   $ 153,000    
The 1044 N Lease [Member]          
Area of Real Estate Property (Square Foot) | ft² 1,719   1,719    
Customer Concentration Risk [Member] | Revenue Benchmark [Member]          
Concentration Risk, Number of Customers 7 8 12 13  
Concentration Risk, Significant Customers 4 3 2 3  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]          
Concentration Risk, Number of Customers 3 4 4 6  
Revenue from Contract with Customer, Excluding Assessed Tax $ 127,000 $ 133,000 $ 314,000 $ 509,000  
Concentration Risk, Percentage 36.00% 16.00% 15.10% 25.60%  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Four Significant Customers [Member]          
Revenue from Contract with Customer, Excluding Assessed Tax $ 297,000 $ 697,000   $ 1,263,000  
Concentration Risk, Percentage 84.10% 83.40%   63.70%  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Two Significant Customers [Member]          
Revenue from Contract with Customer, Excluding Assessed Tax     $ 1,137,000    
Concentration Risk, Percentage     54.70%    
Customer Concentration Risk [Member] | Accounts Receivable [Member]          
Concentration Risk, Number of Customers     10   6
Concentration Risk, Significant Customers     4   3
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Non-US [Member]          
Concentration Risk, Number of Customers     3   4
Concentration Risk, Percentage     34.80%   27.40%
Accounts Receivable, after Allowance for Credit Loss $ 145,000   $ 145,000   $ 91,000
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Four Significant Customers [Member]          
Concentration Risk, Percentage     73.00%    
Accounts Receivable, after Allowance for Credit Loss $ 305,000   $ 305,000    
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]          
Concentration Risk, Percentage         88.20%
Accounts Receivable, after Allowance for Credit Loss         $ 291,000
Supplier Concentration Risk [Member] | Contract Research Organizations [Member]          
Concentration Risk, Number of Suppliers 3   3    
Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | Three CROs [Member]          
Concentration Risk, Percentage 93.40% 99.50% 96.40% 97.40%  
Research Services Purchased $ 977,000 $ 1,352,000 $ 3,639,000 $ 4,146,000  
Supplier Concentration Risk [Member] | Accounts Payable [Member]          
Concentration Risk, Number of Suppliers     3    
Supplier Concentration Risk [Member] | Accounts Payable [Member] | Three CROs [Member]          
Concentration Risk, Percentage     87.60%   79.70%
Accounts Payable 526,000   $ 526,000   $ 1,018,000
Inzymes Agreement APS [Member]          
Non-refundable Upfront Payment, Received 600,000   600,000    
Revenue from Contract with Customer, Excluding Assessed Tax $ 67,000   67,000    
Alphazyme [Member]          
Proceeds from Sale, Maturity and Collection of Investments     $ 1,300,000